论文部分内容阅读
我院于1979～1991年收治经初治获得完全缓解而复发的儿童非何杰金氏淋巴瘤71例，均经病理证实。分期：Ⅰ期2例，Ⅱ期40例，Ⅲ期14例，Ⅳ期15例。71例中68例给予COCP/CHOP交替化疗4～8周期，3例沿用初治方案COCP化疗4周期。结果：CR34例，占47．9％，PR22例，占31．0％，有效率为78．9％，1、3、5年生存率分别为53．5％、26．8％、21．1％，再化疗疗效较好。本文且按复发时间、近期缓解度、部分临床特点分组进行了1、3、5年生存率的对比，结果表明：1年内复发患者组1、3、5年生存率分别低于1年后复发者（P＜0.05）；经再化疗获得CR组分别高于未获得CR组（P＜0．05）；无B症状组分别高于伴B症状组，但经统计学处理，P值分别＞0．05。作者认为对复发性NHL患者的治疗，应趋向于多种互不交叉耐药的化疗方案交替治疗，争取获得CR，提高生存率。
In our hospital from 1979 to 1991, 71 children with non-Hodgkin’s lymphoma who had been completely relieved and relapsed after initial treatment were confirmed by pathology. Staging: Ⅰ in 2 cases, Ⅱ in 40 cases, Ⅲ in 14 cases, Ⅳ in 15 cases. In 71 cases, 68 cases were given COCP / CHOP alternating chemotherapy for 4 to 8 cycles, and 3 patients were treated with the initial regimen COCP chemotherapy for 4 cycles. Results: CR34 cases, accounting for 47.9%, PR22 cases, accounting for 31.0%, the effective rate was 78.9%, 1,3,5-year survival rates were 53.5%, 26.8%, 21 respectively. 1%, then the better effect of chemotherapy. According to the recurrence time, recent remission, and some clinical features, the 1, 3 and 5-year survival rates were compared between groups. The results showed that the 1,3 and 5-year survival rates of recurrence patients within 1 year were less than 1 year respectively (P <0.05). The CR rates in re-treatment group were higher than those in CR group (P <0.05), those in non-B group were higher than those in B group 0.05. The authors believe that the treatment of recurrent NHL patients should tend to a variety of non-cross-resistant chemotherapy regimens alternately treatment for CR, improve survival.